image
Healthcare - Biotechnology - NASDAQ - US
$ 8.25
1.14 %
$ 717 M
Market Cap
-1.6
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one IMNM stock under the worst case scenario is HIDDEN Compared to the current market price of 8.25 USD, Immunome, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one IMNM stock under the base case scenario is HIDDEN Compared to the current market price of 8.25 USD, Immunome, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one IMNM stock under the best case scenario is HIDDEN Compared to the current market price of 8.25 USD, Immunome, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IMNM

image
$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
9.04 M REVENUE
-35.50%
-306 M OPERATING INCOME
-179.19%
-293 M NET INCOME
-174.29%
-111 M OPERATING CASH FLOW
-1363.98%
-85.1 M INVESTING CASH FLOW
-179.04%
241 M FINANCING CASH FLOW
106.63%
2.74 M REVENUE
-5.91%
-83 M OPERATING INCOME
-64.23%
-80.2 M NET INCOME
-70.38%
-42.1 M OPERATING CASH FLOW
-23.10%
9.76 M INVESTING CASH FLOW
-59.51%
20.1 M FINANCING CASH FLOW
6485.25%
Balance Sheet Immunome, Inc.
image
Current Assets 221 M
Cash & Short-Term Investments 217 M
Receivables 0
Other Current Assets 4.04 M
Non-Current Assets 18.9 M
Long-Term Investments 0
PP&E 14.4 M
Other Non-Current Assets 4.51 M
90.45 %5.99 %Total Assets$240.2m
Current Liabilities 54.3 M
Accounts Payable 14.2 M
Short-Term Debt 63 K
Other Current Liabilities 40.1 M
Non-Current Liabilities 4.77 M
Long-Term Debt 4.77 M
Other Non-Current Liabilities 0
24.02 %67.80 %8.07 %Total Liabilities$59.1m
EFFICIENCY
Earnings Waterfall Immunome, Inc.
image
Revenue 9.04 M
Cost Of Revenue 0
Gross Profit 9.04 M
Operating Expenses 315 M
Operating Income -306 M
Other Expenses -12.8 M
Net Income -293 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)9m09m(315m)(306m)13m(293m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-3382.37% OPERATING MARGIN
-3382.37%
-3240.38% NET MARGIN
-3240.38%
-161.71% ROE
-161.71%
-121.95% ROA
-121.95%
-164.41% ROIC
-164.41%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Immunome, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)20192019202020202021202120222022202320232024202420252025
Net Income -293 M
Depreciation & Amortization 2.1 M
Capital Expenditures -7.17 M
Stock-Based Compensation 15.7 M
Change in Working Capital 14.9 M
Others 155 M
Free Cash Flow -118 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Immunome, Inc.
image
Wall Street analysts predict an average 1-year price target for IMNM of $28.5 , with forecasts ranging from a low of $23 to a high of $35 .
IMNM Lowest Price Target Wall Street Target
23 USD 178.79%
IMNM Average Price Target Wall Street Target
28.5 USD 245.45%
IMNM Highest Price Target Wall Street Target
35 USD 324.24%
Price
Max Price Target
Min Price Target
Average Price Target
35353030252520201515101055Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership Immunome, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
279 K USD 2
9-12 MONTHS
0 USD 0
Bought
2.38 M USD 3
0-3 MONTHS
1.31 M USD 3
3-6 MONTHS
97.6 K USD 1
6-9 MONTHS
1.42 M USD 2
9-12 MONTHS
7. News
Immunome: Transformed Pipeline Offers Multiple Catalysts Immunome's unique human immune memory-based discovery engine and strategic pipeline expansion in oncology present a compelling investment opportunity, especially post-merger with Morphimmune. The company's strong financial position, with a cash runway extending through 2027, supports ongoing clinical development and potential market entry for key assets. Lead assets IM-1021 (ROR1 ADC) and IM-3050 (FAP RLT) entering Phase 1 trials, alongside varegacestat's Phase 3 progress, offer multiple near-term catalysts. seekingalpha.com - 2 weeks ago
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 12:45 p.m. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at ww. businesswire.com - 4 weeks ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 228,000 shares of common stock to five new employees under the Company's 2024 Induce. businesswire.com - 4 weeks ago
Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates Immunome, Inc. (IMNM) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.54 per share a year ago. zacks.com - 1 month ago
Immunome Reports Full Year 2024 Financial Results and Provides Business Update BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2024 and provided a business update. “Immunome's efficient execution in 2024 laid the foundation for a productive 2025,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “We are pleased with the progress of our pipeline and, with multiple. businesswire.com - 1 month ago
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC. “Immunome is developing differentiated ADCs that we believe can greatly benefit cancer patients,” said Bob Lechleider, M.D., Chief Medical Officer at Immunome. “The dosing of our first patient with IM-1021. businesswire.com - 1 month ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 3, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 49,000 shares of common stock to four new employees under the Company's 2024 Inducem. businesswire.com - 1 month ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 3, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 51,000 shares of common stock to four new employees under the Company's 2024 Indu. businesswire.com - 2 months ago
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 22,258,064 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,903,225 shares, at a price to the public of $7.75 per share. The gross proceeds to Immunome from the offering, befo. businesswire.com - 3 months ago
Immunome Can Take The Fight To Competitors With Varegacestat Immunome Can Take The Fight To Competitors With Varegacestat seekingalpha.com - 3 months ago
Immunome Announces Pricing of Upsized Public Offering of Common Stock BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 19,354,839 shares of its common stock at a price to the public of $7.75 per share. All of the shares are to be sold by Immunome. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering ex. businesswire.com - 3 months ago
Immunome Announces Proposed Public Offering of Common Stock BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $125.0 million of shares of its common stock. All of the shares are being offered by Immunome. In connection with the proposed offering, Immunome expects to grant the underwriters a 30-da. businesswire.com - 3 months ago
8. Profile Summary

Immunome, Inc. IMNM

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 717 M
Dividend Yield 0.00%
Description Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Contact 665 Stockton Drive, Exton, PA, 19341 https://immunome.com
IPO Date Oct. 2, 2020
Employees 118
Officers Dr. Philip Tsai Chief Technical Officer Mr. Roee Shahar Executive Vice President of Commercial Mr. Max Rosett Chief Financial Officer Dr. Clay B. Siegall Ph.D. Chairman, President & Chief Executive Officer Dr. Robert J. Lechleider M.D. Chief Medical Officer Mr. Kinney Horn Chief Business Officer Dr. Jack Higgins Ph.D. Chief Scientific Officer Ms. Sandra G. Stoneman Esq., J.D. Chief Legal Officer, General Counsel & Corporate Secretary